L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
about
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress(1)H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy.Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.Ammonia increases paracellular permeability of rat brain endothelial cells by a mechanism encompassing oxidative/nitrosative stress and activation of matrix metalloproteinases.Recent developments in acute liver failureHepatic encephalopathy as a complication of liver cirrhosis: an Asian perspective.Critical care of the end-stage liver disease patient awaiting liver transplantation.Ammonia-lowering strategies for the treatment of hepatic encephalopathy.Ornithine phenylacetate revisited.The brain in acute on chronic liver failure.Pharmacotherapy for hyperammonemia.Management in acute liver failure.Acute-on-chronic liver failure: recent update.Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.(1)H and (31)P magnetic resonance spectroscopy in a rat model of chronic hepatic encephalopathy: in vivo longitudinal measurements of brain energy metabolism.Impaired gluconeogenesis in a porcine model of paracetamol induced acute liver failure.Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.Induction of systemic oxidative stress leads to brain oedema in portacaval shunted rats.Safety, Tolerability and Pharmacokinetics of L-Ornithine Phenylacetate in Patients with Acute Liver Injury/Failure and Hyperammonemia.L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.Alternative pathway therapy for hyperammonemia in liver failure.Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.The Pharmabiotic Approach to Treat Hyperammonemia.Acute effects of phenylbutyrate on glutamine, branched-chain amino acid and protein metabolism in skeletal muscles of rats.Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.Phenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized rats.What we know: the inflammatory basis of hepatic encephalopathy.Management of hepatic encephalopathy
P2860
Q27023122-83D72514-F62D-4358-8C78-0E23E2C0DC53Q30978412-11DCE805-2E72-4239-9142-0237B24A8E8CQ33578206-DFCF7636-6E48-413A-9436-5A0F1008EAEBQ34039017-C07E7025-8414-4EDF-9172-3E2A02048865Q35830845-94E03FCC-3874-4EB5-BB9E-CC0FCBDE472AQ36551050-FEAED08D-C770-4A9E-B0E2-DFFF5EEABE5CQ37764962-95BBC66C-474C-4225-A031-3DD8260B71F2Q37867071-9BB78FC9-38F4-41C6-B2C7-B3E7BA33BB0CQ38032730-FE144145-A23B-4896-A0C9-881BAC32D565Q38086119-46AB2C8F-A8BC-4383-8EA1-E77B6E94F838Q38212568-7539CCB0-DA10-412D-9ABE-7A448C701239Q38230555-D59CB50F-C372-4043-9E9E-A0A428439021Q38515260-F1ED7699-EDE3-40DA-976D-7786727A7BA1Q38698971-28F6966C-E646-488A-BBA0-818684E583E1Q39658369-43727067-C6CC-4EA2-AC45-332C3196195CQ40647592-8DAF2E11-675A-4A22-BC58-2ADC39739FD4Q42709555-E53083EF-49C2-435A-8757-5D83FEB6A6F7Q42732353-DED0BAC0-E04C-4CA5-8E43-BDC98FC396B8Q43521848-34CB550F-2C2A-4AFA-8BE3-4AC23EC084D0Q45071236-EB778987-45F5-474E-AD8B-D08FB9D73DB2Q45147300-090B56FF-53F5-4E52-97F7-58A674185C2AQ46012964-F57037D4-D405-40BD-98C2-1B4337319951Q47312982-BCE2D78E-5BD7-40EE-8E8D-534BD5D0386DQ47386646-E7D44693-7484-49D7-A3EA-6195B4B122F1Q47831420-E088111D-0568-4874-907B-AB70F69F8EE8Q48267849-E818D5CC-23ED-4E0D-BBF9-3E605699F14DQ48793739-14217CEB-A3F3-4316-81C3-C73BF38EEEBEQ48909759-1B1680C6-B0A5-42EF-A07C-A8EAA9DCBED1Q51661337-322B88A7-74EA-4911-B178-1ECE8C49D6E3Q52147599-0D0FD8EC-AD5C-4AFA-A95E-CEA09EF8289BQ58687496-B7AC219B-8774-4B56-AA42-41FC8579F24A
P2860
L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@en
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@nl
type
label
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@en
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@nl
prefLabel
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@en
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@nl
P2093
P2860
P356
P1433
P1476
L-ornithine and phenylacetate ...... brain water in cirrhotic rats.
@en
P2093
Abeba Habtesion
Claudia Zwingmann
D Ceri Davies
Gavin Wright
Lars M Ytrebø
Nathan A Davies
Ole-Martin Fuskevåg
Rajiv Jalan
Stephen J Hodges
P2860
P304
P356
10.1002/HEP.22897
P407
P577
2009-07-01T00:00:00Z